Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Capital Leases (2016 - 2017)

Neurocrine Biosciences' Capital Leases history spans 8 years, with the latest figure at $544000.0 for Q1 2017.

  • For Q1 2017, Capital Leases fell 32.76% year-over-year to $544000.0; the TTM value through Mar 2017 reached $544000.0, down 32.76%, while the annual FY2016 figure was $617000.0, 60.32% down from the prior year.
  • Capital Leases reached $544000.0 in Q1 2017 per NBIX's latest filing, down from $617000.0 in the prior quarter.
  • In the past five years, Capital Leases ranged from a high of $3.0 million in Q1 2013 to a low of $544000.0 in Q1 2017.
  • Average Capital Leases over 5 years is $1.8 million, with a median of $2.1 million recorded in 2015.
  • Peak YoY movement for Capital Leases: skyrocketed 32.63% in 2013, then plummeted 61.22% in 2016.
  • A 5-year view of Capital Leases shows it stood at $2.7 million in 2013, then fell by 17.5% to $2.2 million in 2014, then decreased by 29.67% to $1.6 million in 2015, then plummeted by 60.32% to $617000.0 in 2016, then dropped by 11.83% to $544000.0 in 2017.
  • Per Business Quant, the three most recent readings for NBIX's Capital Leases are $544000.0 (Q1 2017), $617000.0 (Q4 2016), and $649000.0 (Q3 2016).